Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 13, 2006, Pages 3595-3599

  McBride, Christopher M ^a   Renhowe, Paul A ^a   Heise, Carla ^a   Jansen, Johanna M ^a   Lapointe, Gena ^a   Ma, Sylvia ^a   Piñeda, Ramon ^a   Vora, Jayesh ^a   Wiesmann, Marion ^a   Shafer, Cynthia M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Basic fibroblast growth factor (bFGF); Indazole benzimidazole; Platelet derived growth factor (PDGF); Receptor tyrosine kinase (RTK); Vascular endothelial growth factor (VEGF)

Indexed keywords

INDAZOLE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG INHIBITION; DRUG SYNTHESIS; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; INDAZOLES; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTOR PROTEIN-TYROSINE KINASES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646852070     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.03.069     Document Type: Article

References (22)

1. Folkman J. Nat. Med. 1 (1995) 27
2. Kerbel R.S. Carcinogenesis 21 (2000) 505
3. Carmeliet P. Nat. Med. 9 (2003) 653
4. Ferrara N. Oncologist 9 (2004) 2
5. Blume-Jensen P., and Hunter T. Nature 411 (2001) 355
6. 'FDA Approves New Treatment for Advanced Kidney Cancer,' The Food and Drug Administration Press Release, 2005.
7. 'FDA Approves Pfizer's Sutent for Kidney and Bowel Cancers,' Pfizer, Inc., 2006.
8. Hecht, J. R.; Trarbach, T.; Jaeger, E.; Hainsworth, J.; Wolff, R.; Lloyd, K.; Bodoky, G.; Borner, M.; Laurent, D.; Jacques, C. In 41st ASCO Annual Meeting; Orlando, FL, 2005; Vol. 3.
9. Antonios-McCrea W.R., Frazier K.A., Jazan E.M., Machajewski T.D., McBride C.M., Pecchi S., Renhowe P.A., Shafer C.M., and Taylor C. Tetrahedron Lett. 47 (2006) 657
10. Lopes de Menezes D.E., Peng J., Garrett E.N., Louie S.G., Lee S.H., Wiesmann M., Tang Y., Shephard L., Goldbeck C., Oei Y., Ye H., Aukerman S.L., and Heise C. Clin. Cancer Res. 11 (2005) 5281
11. Shafer, C. M. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004; 2004; ORGN-248.
12. The lead compound from this series, CHIR-258, is currently in Phase I clinical trials.
13. During the course of this project, two patent applications on indazole benzimidazole compounds as tyrosine kinase and serine-threonine kinase inhibitors were published (WO 2001002369 and WO 2001053268). The compounds described in those publications, however, were significantly different so as to not affect our program.
14. For both of the biochemical VEGFR2 and PDGFRβ assays, the highly conserved mouse homologues have been used.
15. The VEGFR-2 homology model was built using Chemical Computing Group's MOE software. Default settings were used in the alignment and homology modeling module and the FGFR1 crystal structure (2FGI) from the Brookhaven Protein Data Bank was used as a template. Compound 18 was built and optimized in the active site of the homology model using the Flo+apr2003 software from Thistlesoft.
16. Supplemental materials contains an overlay of compound 16 and PD173074.
17. Mohammadi M., Froum S., Hamby J.M., Schroeder M.C., Panek R.L., Lu G.H., Eliseenkova A.V., Green D., Schlessinger J., and Hubbard S.R. EMBO J. 17 (1998) 5896
18. Anderson W.K., Gopalsamy A., and Reddy P.S. J. Med. Chem. 37 (1994) 1955
19. Buchi G., Lee G.C.M., Yang D., and Tannenbaum S.R. J. Am. Chem. Soc. 108 (1986) 4115
20. Allen, D. G.; Eldred, C. D.; Judkins, B. D.; Mitchell, W. L. In PCT Int. Appl.: WO 9749699, 1997; pp. 40.
21. 2O and adding HCl (2 M) until the solid dissolved. The solution was lyophilized to give 18 as a yellow solid (2.1 g, 63%).
22. Further synthetic details and characterization for 18 are included in the Supplemental Material.